LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Radicicol | 3.33 | uM | LJP6 | 72 | hr | 2543 | 2083 | 5578 | 0.3734 | -0.1517 |
| SK-BR-3 | Seliciclib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 4738 | 5578 | 0.8494 | 0.7231 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 5660 | 5578 | 1.0146 | 1.0269 |
| SK-BR-3 | XL147 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 6038 | 5578 | 1.0823 | 1.1513 |
| SK-BR-3 | Saracatinib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 4591 | 5578 | 0.8231 | 0.6748 |
| SK-BR-3 | Selumetinib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 5397 | 5578 | 0.9676 | 0.9404 |
| SK-BR-3 | Sirolimus | 3.33 | uM | LJP6 | 72 | hr | 2543 | 3462 | 5578 | 0.6207 | 0.3029 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 5732 | 5578 | 1.0275 | 1.0505 |
| SK-BR-3 | SU11274 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 5612 | 5578 | 1.0061 | 1.0112 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 4313 | 5578 | 0.7732 | 0.5832 |
| SK-BR-3 | TGX221 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 5576 | 5578 | 0.9996 | 0.9992 |
| SK-BR-3 | Torin1 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1639 | 5578 | 0.2939 | -0.2978 |
| SK-BR-3 | Torin2 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 1676 | 5578 | 0.3005 | -0.2857 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 1973 | 5578 | 0.3537 | -0.1880 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 4303 | 5578 | 0.7713 | 0.5797 |
| SK-BR-3 | TWS119 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 3792 | 5578 | 0.6798 | 0.4115 |
| SK-BR-3 | Vemurafenib | 3.33 | uM | LJP5 | 72 | hr | 2543 | 5733 | 5578 | 1.0277 | 1.0510 |
| SK-BR-3 | Withaferin A | 3.33 | uM | LJP5 | 72 | hr | 2543 | 1817 | 5578 | 0.3258 | -0.2391 |
| SK-BR-3 | Withaferin A | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1408 | 5578 | 0.2525 | -0.3740 |
| SK-BR-3 | WYE-125132 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1935 | 5578 | 0.3469 | -0.2004 |
| SK-BR-3 | WZ3105 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 1303 | 5578 | 0.2337 | -0.4085 |
| SK-BR-3 | XMD11-50 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 3048 | 5578 | 0.5464 | 0.1662 |
| SK-BR-3 | Y39983 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 3693 | 5578 | 0.6620 | 0.3787 |
| SK-BR-3 | YM 201636 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 5005 | 5578 | 0.8972 | 0.8111 |
| SK-BR-3 | ZSTK474 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 2036 | 5578 | 0.3650 | -0.1671 |